Press Release Archive

06.08.2016

Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

06.08.2016

Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA

06.07.2016

A Mother’s Mission to Help Prevent Another Life Lost to MenB

06.07.2016

Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis

06.06.2016

ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma

06.06.2016

Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer

06.05.2016

Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

06.04.2016

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

05.31.2016

BioRap Technologies to enter strategic collaboration with Pfizer Inc. to research and develop novel immunomodulators

05.23.2016

CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP

05.20.2016

Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine)

05.19.2016

Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression

05.18.2016

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

05.18.2016

Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

05.17.2016

Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)

05.16.2016

Pfizer to Acquire Anacor

05.13.2016

Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

05.11.2016

Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

05.10.2016

AM‐Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

05.10.2016

First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics

05.05.2016

WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases

05.03.2016

PFIZER REPORTS FIRST-QUARTER 2016 RESULTS

04.28.2016

Pfizer Hosts Annual Meeting of Shareholders

04.26.2016

AM‐Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial

04.26.2016

Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

04.22.2016

CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

04.21.2016

Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

04.19.2016

AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design” in 2016 CARE Awards

04.19.2016

Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)

04.07.2016

Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care

04.06.2016

Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

04.06.2016

Pfizer Announces Termination of Proposed Combination with Allergan

04.05.2016

FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

04.05.2016

Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

04.05.2016

Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

04.04.2016

Pfizer and Allergan Issue Statement

04.04.2016

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

04.01.2016

Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

03.31.2016

Pfizer Inc. (NYSE: PFE) today issued the following statement:

03.30.2016

Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

03.30.2016

Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session

03.23.2016

Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis

03.22.2016

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

03.22.2016

Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

03.18.2016

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

03.16.2016

Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

03.15.2016

Pfizer Celebrates a Year of Achievements in 2015 Annual Review

03.11.2016

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer